欢迎你:
个人中心
Zentalis and Pfizer plan to jointly advance the clinical development of ZN-c3, a selective Wee1 inhibitor designed to induce synthetic lethality in cancer cells,$Zentalis(ZNTL)$
$25m equity investment at $26.21/share。除了阿斯利康,国内有首药控股,英派,上海医药等开发Wee1。
此文仅代表作者观点,点击可查看作者简介
版主: